

Market Outlook

The Nifty 50 closed at 25,574, marking a positive session and extending its rebound from the 50-day EMA on the daily chart. On the derivatives front, fresh Put OI build-up at the 25,500 strike indicates a near-term support zone, while Call OI accumulation at the 25,650 and 25,700 strikes suggests immediate resistance levels. From a technical perspective, the 20-day EMA is currently positioned near the 25,600 mark. A sustained close above this level may pave the way for an upside move towards the 25,800 area.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25574.35	0.32
SENSEX	83535.35	0.38
BANKNIFTY	57937.55	0.10
INDIA VIX	12.30	-2.05

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-919.82	2.48%
Index Options	-9093.97	7.62%
Stock Futures	198.48	-0.15%
Stock Options	-370.96	5.08%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-4114.85	-5748	-115968
DII	5805.26	22483	464933

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ETERNAL	24280544	20.18	26.04
HDFCBANK	11329554	-0.25	6.56
POWERGRID	7010409	-7.77	-5.81
ICICIBANK	6119354	6.64	10.66
INFY	5871349	-6.35	11.66
BHARTIARTL	5484860	-8.68	-89.41
SHRIRAMFIN	5169289	11.33	-11.69
JIOFIN	4508543	0.58	-5.28
WIPRO	4425382	-0.08	55.18
RELIANCE	4298505	-0.21	-9.63


NIFTY

Nifty	25694.50
OI (In contracts)	268665
CHANGE IN OI (%)	0.00
PRICE CHANGE (%)	0.40
IMPLICATION	NEUTRAL

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
NYKAA	259.31	5.70	20444	10.30
AMBER	6939	0.20	15934	9.40
TECHM	1404.6	0.90	34818	7.30
SAIL	145.19	2.50	43384	5.30
BHEL	274.4	3.60	23328	4.60


BANKNIFTY

Banknifty	58252.20
OI (In contracts)	61444
CHANGE IN OI (%)	7.40
PRICE CHANGE (%)	0.10
IMPLICATION	LONG BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
TRENT	4304.9	-7.20	98497	17.10
FORTIS	995.3	-2.70	15012	12.00
LICI	902.25	-2.90	15552	11.40
NCC	189.03	-3.60	8444	6.40
MANKIND	2247.6	-1.00	9243	6.20

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
AUBANK	7682000	6004000	1.28
SHRIRAMFIN	21270150	17848050	1.19
LTF	47971076	41077362	1.17
PETRONET	15075000	13057200	1.15
BPCL	17459000	15537325	1.12
CANBK	109937250	102255750	1.08
POWERINDIA	287800	267250	1.08
IOC	58236750	54775500	1.06
BHEL	36857625	35424375	1.04
JINDALSTEL	5323750	5185625	1.03

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
BLUESTARCO	819000	2849275	0.29
GMRAIRPORT	41982525	128416725	0.33
BHARTIARTL	9479100	28050650	0.34
DELHIVERY	9352025	27441875	0.34
NESTLEIND	2025500	5933500	0.34
SHREECEM	48675	144150	0.34
MAZDOCK	1716775	4527250	0.38
PPLPHARMA	5832500	15375250	0.38
YESBANK	171454300	452100700	0.38
360ONE	663500	1680500	0.39

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2392	2409	2381	2365	2353
ADANIPORTS	1456	1465	1450	1442	1436
APOLLOHOSP	7645	7725	7598	7519	7472
ASIANPAINT	2680	2704	2649	2624	2593
AXISBANK	1234	1244	1228	1217	1211
BAJAJ-AUTO	8873	8936	8797	8734	8658
BAJAJFINSV	2144	2157	2122	2109	2087
BAJFINANCE	1097	1106	1082	1073	1058
BEL	422	424	418	416	412
BHARTIARTL	2036	2048	2015	2003	1983
CIPLA	1524	1532	1515	1507	1498
COALINDIA	385	387	382	380	377
DRREDDY	1210	1217	1204	1198	1192
EICHERMOT	6955	7018	6893	6830	6767
ETERNAL	307	312	305	300	298
GRASIM	2802	2828	2769	2743	2710
HCLTECH	1560	1573	1538	1526	1503
HDFCBANK	997	1003	991	984	979
HDFCLIFE	759	765	755	750	746
HINDALCO	799	809	793	783	778
HINDUNILVR	2432	2446	2424	2410	2401
ICICIBANK	1356	1359	1350	1347	1341
INDIGO	5663	5711	5615	5567	5519
INFY	1510	1522	1491	1479	1461
ITC	409	410	407	406	404

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	305	306	303	302	300
JSWSTEEL	1191	1197	1184	1177	1170
KOTAKBANK	2116	2130	2101	2087	2072
LT	3952	3972	3932	3913	3893
M&M	3713	3750	3683	3646	3616
MARUTI	15768	15888	15594	15474	15300
MAXHEALTH	1132	1161	1117	1088	1073
NESTLEIND	1275	1282	1270	1263	1259
NTPC	329	331	327	325	323
ONGC	254	257	252	249	247
POWERGRID	271	273	269	267	265
RELIANCE	1507	1517	1494	1483	1470
SBILIFE	2010	2029	1999	1980	1969
SBIN	963	971	957	949	943
SHRIRAMFIN	832	839	825	818	811
SUNPHARMA	1707	1713	1700	1694	1687
TATACONSUM	1170	1194	1156	1132	1117
TATASTEEL	183	184	182	181	180
TCS	3068	3095	3032	3004	2969
TECHM	1413	1422	1402	1393	1381
TITAN	3831	3850	3810	3791	3771
TMPV	416	420	411	407	402
TRENT	4490	4674	4385	4201	4096
ULTRACEMCO	11900	12014	11829	11715	11644
WIPRO	243	244	240	238	236

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results